| Co-Investigator(Kenkyū-buntansha) |
竹ノ谷 文子 星薬科大学, 薬学部, 准教授 (30234412)
中町 智哉 富山大学, 学術研究部理学系, 講師 (30433840)
亀井 淳三 星薬科大学, 薬学部, 教授 (40161236)
宮田 篤郎 鹿児島大学, 医歯学域医学系, 教授 (60183969)
土肥 謙二 昭和大学, 医学部, 教授 (20301509)
|
|---|
| Budget Amount *help |
¥46,150,000 (Direct Cost: ¥35,500,000、Indirect Cost: ¥10,650,000)
Fiscal Year 2020: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
Fiscal Year 2019: ¥10,140,000 (Direct Cost: ¥7,800,000、Indirect Cost: ¥2,340,000)
Fiscal Year 2018: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
Fiscal Year 2017: ¥9,100,000 (Direct Cost: ¥7,000,000、Indirect Cost: ¥2,100,000)
Fiscal Year 2016: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
|
|---|
| Outline of Final Research Achievements |
Though the preparation of the KO-mouse of PAC1 receptor which is directly concerned in the delayed neuronal death was possible, there are many individuals who die immediately after the birth, and it is necessary to increase the number of individuals.
It was proven that the intrinsic PACAP suppressed the delayed neuronal death of the hippocampus in the animal experiment using PACAP KO mouse, and it was also concerned in nerve regeneration and newborn. In addition, it was also clarified that PACAP manifested CRMP2 which is the axon extension factor in the culture experiment, and that it promotes the axon extension through NrdA1 which is the transcription factor. However, primate marmosets are not suitable for purpose because animals cannot increase a small number of animals. Morever, the superagonist of PAC1R is being searched at present.
|
